US4427782A - Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis - Google Patents
Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis Download PDFInfo
- Publication number
- US4427782A US4427782A US06/240,223 US24022381A US4427782A US 4427782 A US4427782 A US 4427782A US 24022381 A US24022381 A US 24022381A US 4427782 A US4427782 A US 4427782A
- Authority
- US
- United States
- Prior art keywords
- antigen
- protein
- chlamydia trachomatis
- daltons
- trachomatis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000606153 Chlamydia trachomatis Species 0.000 title claims abstract description 59
- 102000036639 antigens Human genes 0.000 title claims abstract description 51
- 239000000427 antigen Substances 0.000 title claims abstract description 43
- 229940038705 chlamydia trachomatis Drugs 0.000 title claims abstract description 20
- 101710116435 Outer membrane protein Proteins 0.000 title claims description 17
- 238000002955 isolation Methods 0.000 title description 8
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 title description 2
- 108091007433 antigens Proteins 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 239000003599 detergent Substances 0.000 claims abstract description 19
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 13
- 241000894007 species Species 0.000 claims abstract description 11
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 9
- 206010061041 Chlamydial infection Diseases 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 201000000902 chlamydia Diseases 0.000 claims abstract description 5
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 claims abstract description 5
- 238000003556 assay Methods 0.000 claims description 17
- 241000498849 Chlamydiales Species 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 6
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 108010077895 Sarcosine Proteins 0.000 claims description 3
- 229940043230 sarcosine Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 241000606161 Chlamydia Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical group [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 3
- 108010052285 Membrane Proteins Proteins 0.000 claims 3
- 150000008051 alkyl sulfates Chemical class 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 102000007397 Species specific proteins Human genes 0.000 claims 1
- 108020005719 Species specific proteins Proteins 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 9
- 101710164702 Major outer membrane protein Proteins 0.000 abstract description 4
- 238000004587 chromatography analysis Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 23
- 238000012360 testing method Methods 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- 241001185363 Chlamydiae Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000000143 urethritis Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010035742 Pneumonitis Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000000760 immunoelectrophoresis Methods 0.000 description 3
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241001647378 Chlamydia psittaci Species 0.000 description 2
- 241000324543 Chlamydia psittaci 6BC Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ANVJDDFUALPTBF-UHFFFAOYSA-N 2-aminoacetic acid 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O.OCC(N)(CO)CO ANVJDDFUALPTBF-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical group O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- MPBRYMWMMKKRGC-UHFFFAOYSA-M carbocyanin DBTC Chemical compound [Br-].C1=CC=CC2=C([N+](=C(C=C(C)C=C3N(C4=C5C=CC=CC5=CC=C4S3)CC)S3)CC)C3=CC=C21 MPBRYMWMMKKRGC-UHFFFAOYSA-M 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960005133 diatrizoate meglumine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Definitions
- This invention relates generally to the isolation of cell protein of microorganisms which exhibit antigenic properties and more particularly to the isolation of the principal outer membrane protein of Chlamydia trachomatis, which protein exhibits antigenic properties common to all the Chlamydia trachomatis serotypes.
- Chlamydia trachomatis is one of the two microorganism species of the genus Chlamydiaceae, order Chlamydiales. The other species is Chlamydia psittaci. Chlamydia trachomatis in its some 15 various strains, are the etiologic agents for a number of human ocular and genital diseases including trachoma, inclusion, conjunctivitis, lymphogranuloma venereum, "nonspecific" or non-gonococcal urethritis and proctitis. C. trachomatis infection is pervasive throughout the general population. It has been estimated, for instance, that C. trachomatis is accountable for several million cases per year of nongonococcal urethritis.
- C. trachomatis mediated disease is widespread, a reliable, simple and inexpensive test for the organism's presence is highly desirable and of great importance so that proper treatment may be undertaken.
- the only serological test in current use is the microimmunofluoresence test. This test however requires that the strains of C. trachomatis be used as serological test antigen.
- the facilities for conducting this test are available in only a limited number of laboratories throughout the world. The test is very laborious, time consuming and difficult to perform.
- the present invention presents a species specific antigen which comprises the principal outer membrane protein of Chlamydia trachomatis.
- Such protein comprise about 60% of the total associated outer membrane protein of C. trachomatis, and have a size or subunit molecular weight of between 38,000 and 44,000 daltons, with a mean molecular weight of 39,500 daltons.
- this principal outer membrane protein group will be referred to as MP 39.5 signifying "major outer membrane protein having a mean subunit molecular weight of 39,500 daltons".
- MP 39.5 When tested against C. trachomatis antibodies derived from all the serotypes thereof, MP 39.5 reacts with species specificity. Thus MP 39.5 is a C. trachomatis species specific antigen. MP 39.5 is a unique protein common to all C. trachomatis serotypes, and as an antigen provides a basis for the identification of all the C. trachomatis serotypes.
- MP 39.5 is isolated from C. trachomatis elementary bodies, i.e., the intact microorganism cells, by first growing suitable strains of the organism and collecting the elementary bodies free from the growth medium. The purified elementary bodies are treated by means hereinafter described to isolate the outer cell membranes. These outer cell membranes are selectively separated from the cell cytoplasm membrane and protoplasm. The isolated outer cell membranes are then further treated by a method hereinafter described to yield essentially pure MP 39.5.
- the MP39.5 recovered from the outer membranes is then available for either (1) direct reaction with C. trachomatis antibodies generated in the serum of C. trachomatis infected hosts; or (2) to be injected into laboratory animals to produce antiserum against MP39.5.
- the recovered MP39.5 may be utilized in immunodiagnostic assay procedures for C. trachomatis.
- MP39.5 is the principal outer membrane protein of C. trachomatis and it is species specific antigen to all C. trachomatis serotypes.
- isolation of MP39.5 from C. trachomatis elementary bodies is accomplished by an essentially two step extraction procedure.
- purified elementary bodies are contacted with an aqueous solution of a mild anionic sarcosine detergent, preferably sodium N-lauroyl sarcosine (commonly referred to as sarcosyl).
- a mild anionic sarcosine detergent preferably sodium N-lauroyl sarcosine (commonly referred to as sarcosyl).
- the sarcosyl selectively dissolves out the elementary body cytoplasm including the protein, nucleic acids and other molecular structures associated therewith, leaving the elementary body outer membrane as an insoluble residue.
- Electron microscopic studies indicate that the sarcosyl treatment leaves an insoluble residue which consists of uniform particles of single intact double-track unit membranes of a size and morphology characteristic of native chlamydial elementary body outer membrane.
- the residual elementary body membranes are lysed with a strong anionic detergent, preferably sodium dodecyl sulfate, which solubilizes the principal outer membrane protein, MP39.5.
- a strong anionic detergent preferably sodium dodecyl sulfate, which solubilizes the principal outer membrane protein, MP39.5.
- the MP39.5 is then recovered from the detergent solution, and purified to yield the MP39.5 antigen.
- the purified MP39.5 protein when tested against antibody derived from known C. trachomatis serotypes demonstrates that MP39.5 is a species specific antigen of C. trachomatis organisms.
- C. trachomatis organisms The following C. trachomatis strains were used: L2/434/Bu(L2), E/UW-5/Cx(E) and C/TW-3/OT(C). Chlamydiae were grown in HeLa 229 cells as described previously in the publication in October of 1975 in the Journal of Immunology v. 15, pgs 963-968 by Caldwell et.al., entitled "Antigenic Analysis of Chlamydiae by Two-Dimensional Immunoelectrophoresis.” Such disclosure is incorporated herein by reference. The L2 strain was also grown in suspension cultures of L-929 cells. L-cell-propagated L2 organisms were used for the isolation and purification of the 39,500 dalton protein.
- Chlamydiae were harvested from HeLa cell monolayers grown in 150 cm 2 polystyrene culture flasks (Corning Glass Works, Corning, N.Y.) with 90% of the cells containing inclusions at 48 hours postinoculation. Medium was poured off and cells were removed with 4 mm glass beads and 10 ml of cold Hanks' balanced salt solution. These cell suspensions were pooled and the cells ruptured by sonication (Braunsonic Model 1510). This suspension was centrifuged at 500 ⁇ g for 15 min at 4° C.
- the supernatants were layered over 8 ml of a 35% Renographin solution (v/v) (diatrizoate meglumine and diatrizate sodium, 76% for injection, Squibb and Sons, N.Y.) in 0.01 M N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid containing 0.15 M NaCl. They were then centrifuged at 43,000 ⁇ g for 1 hour at 4° C. in an SW 27 rotor (Beckman Instruments Inc., Fullerton, Ca). The pellets were resuspended in 0.01 M sodium phosphate (pH 7.2) containing 0.25 M sucrose and 5 mM L-glutamic acid (SPG).
- v/v Renographin solution
- SPG L-glutamic acid
- Chlamydiae elementary body bands located at the 44/52% Renographin interface, were collected, diluted with three volumes of SPG and then centrifuged at 30,000 ⁇ g for 30 min. The elementary body pellets were washed in SPG to remove residual Renographin. The purified elementary bodies were resuspended in SPG and stored at -80° C. The purity of the elementary body preparations was determined by electron microscopy and Macchiavello stained smears.
- the pellet was washed twice in PBS to remove excess detergent and then resuspended in 0.02 M sodium phosphate, pH 8.0, containing 19 mM MgCl 2 and 25 g/ml deoxyribonuclease (Worthinton Biochemical Corp., Freehold, N.J.) and ribonuclease (Millipore Corp., Freehold, N.J.). This suspension was then incubated for 2 hours at 37° C., centrifuged and the insoluble pellet washed twice with PBS to remove any remaining nucleases. This sarcosyl insoluble material consisted of chlamydial outer membrane complexes (COMC).
- COMPOC chlamydial outer membrane complexes
- This sodium dodecyl sulfate extract enriched in the 39.500 dalton protein, was then dialyzed against 200 volumes of 0.01 M sodium phosphate, pH 6.4, containing 1 mM dithiothreitol (DTT) and 0.1% sodium dodecyl sulfate (column equilibration buffer) for 24 hours with several changes of dialysate.
- This extract was fractionated by hydroxylapatite chromatograpy in the presence of sodium dodecyl sulfate using the technique disclosed by Moss and Rosenblum in J. Bio. Chem., 1972, V. 247, pgs. 5194-5198.
- the dialyzed extract (8-10 ml) was supplied to a pre-equilibrated hydroxylapatite column (0.9 ⁇ 30 cm).
- the column was washed with 100 ml of equilibration buffer and eluted with a 150 ml linear gradient of 0.1 M to 0.6 M sodium phosphate, pH 6.4, containing 1 mM DTT and 0.1% sodium dodecyl sulfate.
- the column eluate was collected in 40 drop fractions at a flow rate of 5-6 ml per hour and spectrophotometrically monitored at 280 nm absorbence. Those fractions showing positive absorbence were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
- the polyacrylamide gels were stained with Coomassie blue for protein and Stains-All to detect nucleic acid and glycolipid moieties.
- the phosphate molarity of every tenth column fraction was determined by measuring total phosphorous and converting to phosphate molarity by using a standard curve prepared wiht known sodium phosphate standards.
- Those fractions that contained only the MP39.5 were pooled and concentrated to a 1-2 ml volume by vacuum dialysis against 0.05 mM Tris-HCl, pH 8.5, containing 0.15 M NaCl and 0.1% sodium dodecyl sulfate. These concentrated preparations were used for performing analytical assays to test for protein purity and as a source of immunogen for the preparation of antisera in laboratory animals.
- the molecular weights of the purified COMC proteins were determined by polyacrylamide gel electrophoresis. Specifically, the Chlamydial proteins were electrophoresed on 12.5% acrylamide slab gels in the discontinuous Tris (hydroxymethyl) aminomethane-glycine (Trisglycine) system described by Laemmli in Nature (London) v. 227, pgs. 680-685 (1970). The ratio of acrylamide to N, N'-methylenebisacrylamide was 30:0.8 in both the 12.5% separating gel and 5% stacking gel.
- Trisglycine discontinuous Tris (hydroxymethyl) aminomethane-glycine
- the protein standards used for estimating chlamydial protein molecular weights were: phosphorylase b (94,000), bovine serum albumin (67,000), ovalbumin (43,000), carbonic anhydrase (30,000), soy bean trypsin inhibitor (20,100) and ⁇ -lactalbumin (14,400) (Pharmacia, Inc., Piscataway, N.J.).
- mice strain 1CR (Charles River Co. Baltimore, MD) were immunized subcutaneously on day 0 with 30 ⁇ g of purified Mp39.5 emulsified with Freund's incomplete adjuvant. Immunizations were repeated with the same amount of purified protein administered subcutaneously without adjuvant on days 16 and 27. Mice were bled by cardiac puncture 5 days after each immunization (days 21 and 32, respectively). The reactivity and specificity of the pooled sera collected from each bleeding was evaluated by indirect immunofluorescence.
- Table 1 presents the results of tests against elementary bodies of the various Chlamydiae serotypes (both trachomatis and psittaci) with the mouse generated antisera.
- the MP39.5 antigen has species specificity against all the C. trachomatis serotypes.
- monospecific antibodies against MP39.5 antigen can be generated by suitable inoculation procedures with laboratory animals such as mice and/or rabbits.
- the animal generated antibodies may be utilized in assays for Chlamydial infection in other mammals. These assays may be conducted in well known procedures for assaying the presence of bacterial antigen in the infected subject.
- either direct or indirect assay procedures can be undertaken with specimens secured from mammals suspected of harboring Chlamydial infections.
- Assay techniques such as enzyme linked immunoabsorbent assays (ELISA) or radioimmune assays (RIA) are suitable for these purposes.
- ELISA enzyme linked immunoabsorbent assays
- RIA radioimmune assays
- monospecific antibody against the MP39.5 protein may be covalently or non-covalently attached to a solid phase support system.
- the support system may be glass, plastics and the like.
- the solid phase support with attached monospecific antibody against MP39.5 may be incubated with a specimen previously secured from the individual suspected with having Chlamydial infection. Prior to incubation, the specimen is treated with a detergent such as sodium dodecyl sulfate or other anionic, nonionic or cationic detergent to extract the MP39.5 outer membrane antigen from any Chlamydial organisms which may be present therein. It is the extracted specimen which is incubated with the solid phase support.
- a detergent such as sodium dodecyl sulfate or other anionic, nonionic or cationic detergent
- radiolabeled antibody the amount of residual radioactivity in the sample may then determined. This value is compared to specimens that have been determined to be free of Chlamydial MP39.5 antigen.
- enzyme conjugated antibody a substitute specific for the enzyme is added to the solid support reaction mixture and the resultant color change is recorded spectrophotometrically. This color change is compared to samples known to be free of Chlamydial MP39.5 antigen.
- MP39.5 antigen is mammalian specimens can be assayed directly.
- Chlamydial (MP39.5) antigen secured as in the procedures set forth above may be covalently or non-covalently bound to a suitable solid phase support system.
- a specimen from the individual suspected of having Chalmydial infection is treated with detergent, e.g., sodium dodecyl sulfate to extract the major outer membrane protein antigen from any C. trachomatis cells which may be present.
- the extract from the specimen may then be mixed with a known quantity of radiolabeled or enzyme conjugated antibody against the MP39.5 antigen, previously secured from a laboratory animal source.
- the specimen extract--antibody mixture may then be incubated with the solid support system and its bound MP39.5 antigen.
- the radioactivity of the solid support system is measured; or color development in the enzyme conjugated system is measured; and compared to specimens similarly treated as standards and which do not contain any Chlamydial antigen.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
TABLE I ______________________________________ Indirect immunofluorescence of Chlamydia with mouse antiserum prepared against purified MP39.5 Reciprocal antibody titer of mouse* anti-MP39.5 Titer after 2nd Titer after 3rd Serotype or immunization immunization Organism strain (day 21) (day 32) ______________________________________ C. trachomatis A -- -- B -- -- Ba 8 128 C -- -- D 8 128 E 8 64 F -- -- G -- -- H -- -- I -- -- J -- -- K 8 128 L1 8 128 L2 64 512 L3 8 128 Mouse -- -- pneumonitis C. psittaci 6BC -- -- Feline -- -- pneumonitis Guinea pig -- -- inclusion conjunctivitis ______________________________________ *Highest dilution of antiserum (starting at 1:8) showing fluorescence. Serum antibody titers are lgG only, no fluorescence was observed with antilgM specific conjugate.
TABLE II ______________________________________ Indirect fluorescent antibody staining of intact Chlamydeae with rabbit antiserum raised against the major outer membrane protein MP39.5 of the L2 C. trachomatis strain. Reciprocal Fluor- escent Antibody Organism Serotype Titer ______________________________________ C. trachomatis A 64 B 4096 Ba 8192 C 64 D 512 E 4096 F 2048 G 4096 H 256 I 64 J 256 K 4096 L1 128 L2 8092 L3 4096 C. psittaci 6BC <8 Mn <8 Feline pneumonitis <8 Guinea pig inclusion <8 conjunctivitis ______________________________________
Claims (19)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/240,223 US4427782A (en) | 1981-03-03 | 1981-03-03 | Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis |
CA000395080A CA1186223A (en) | 1981-03-03 | 1982-01-28 | Isolation of principal outer membrane protein and antigen of chlamydia trachomatis |
AU80190/82A AU549025B2 (en) | 1981-03-03 | 1982-02-04 | Isolation of principal outer membrane protein and antigen of chlamydia trachomatis |
EP82301003A EP0059624B1 (en) | 1981-03-03 | 1982-02-26 | Isolation of principal outer membrane protein and antigen of chlamydia trachomatis |
DE8282301003T DE3266888D1 (en) | 1981-03-03 | 1982-02-26 | Isolation of principal outer membrane protein and antigen of chlamydia trachomatis |
JP57032517A JPS57158725A (en) | 1981-03-03 | 1982-03-03 | Cladimea trachoma strain specific antigen and manufacture |
JP7085455A JP2773816B2 (en) | 1981-03-03 | 1995-04-11 | Methods for analyzing the presence of Chlamydia infection and species-specific antigens of Chlamydia trachomatis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/240,223 US4427782A (en) | 1981-03-03 | 1981-03-03 | Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis |
Publications (1)
Publication Number | Publication Date |
---|---|
US4427782A true US4427782A (en) | 1984-01-24 |
Family
ID=22905652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/240,223 Expired - Lifetime US4427782A (en) | 1981-03-03 | 1981-03-03 | Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis |
Country Status (6)
Country | Link |
---|---|
US (1) | US4427782A (en) |
EP (1) | EP0059624B1 (en) |
JP (2) | JPS57158725A (en) |
AU (1) | AU549025B2 (en) |
CA (1) | CA1186223A (en) |
DE (1) | DE3266888D1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4497899A (en) * | 1982-04-12 | 1985-02-05 | Abbott Laboratories | Immunoassay for Chlamydia trachomatis antigens |
US4683196A (en) * | 1983-12-12 | 1987-07-28 | Meru, Inc. | Method and materials for the identification of lipopolysaccharide producing microorganisms |
WO1987007147A1 (en) * | 1986-05-28 | 1987-12-03 | Murex Corporation | Method for producing monoclonal antibodies to an immunogenic antibody-antigen conjunction |
US4766065A (en) * | 1984-08-23 | 1988-08-23 | Becton Dickinson And Company | Detection of cell membrane protein |
US4916057A (en) * | 1988-02-29 | 1990-04-10 | Kallestad Diagnostics, Inc. | Chlamydia assay employing base treatment |
US4959303A (en) * | 1987-12-21 | 1990-09-25 | Syntex (U.S.A.) Inc. | Assay for antigens by binding immune complexes to solid supports free of protein and non-ionic binders |
US4981685A (en) * | 1986-03-07 | 1991-01-01 | Utah State University Foundation | Bacterial extract vaccines for veterinary application |
US5075221A (en) * | 1988-10-07 | 1991-12-24 | Eastman Kodak Company | Stabilized extraction composition containing a sulfhydryl-containing reducing agent and its use in chlamydial and gonococcal determinations |
US5132205A (en) * | 1988-10-07 | 1992-07-21 | Eastman Kodak Company | High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen |
US5212062A (en) * | 1991-09-06 | 1993-05-18 | Kansas State University | Method and composition to direct Chlamydia psittaci or Chlamydia trachomatis infection |
US5300632A (en) * | 1986-11-18 | 1994-04-05 | Research Foundation Of State University Of New York | Method for purifying an outer membrane protein of Haemophilus influenzae |
US5318892A (en) * | 1990-05-08 | 1994-06-07 | Hitachi Chemical Co., Ltd. | Method for assaying antibody against Chlamydia trachomatis and diagnostic preparation for chlamydia trachomatis infection |
US5474900A (en) * | 1990-03-16 | 1995-12-12 | Sekisui Chemical Co., Ltd. | Process for preparing purified syphilis antigen from Treponema palljdum |
US5484706A (en) * | 1993-05-19 | 1996-01-16 | Pasteur Sanofi Diagnostics | Immunoassay for analytes in samples using alkylating agents |
US5516638A (en) * | 1992-11-18 | 1996-05-14 | Calypte, Inc. | Immunoassays for the detection of antibodies to Chlamydia trachomatisi in the urine. |
US5554471A (en) * | 1995-10-12 | 1996-09-10 | Xerox Corporation | Combination of toners |
US5725863A (en) * | 1991-09-06 | 1998-03-10 | The United States Of America As Represented By The Secretary Of Agriculture | Polypeptides useful in prevention of chlamydia infection |
US5869608A (en) * | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
WO1999017741A1 (en) * | 1997-10-02 | 1999-04-15 | Antex Biologics Inc. | Chlamydia protein, gene sequence and uses thereof |
US6030799A (en) * | 1985-01-14 | 2000-02-29 | Washington Research Foundation | Immunoassays for detecting chlamydial antigens or antibodies thereto using recombinant or synthetic major outer membrane protein polypeptides as substitute antigens |
US6281199B1 (en) | 1996-10-18 | 2001-08-28 | Pfizer Inc. | Method of treatment of heart disease caused by Chlamydia pneumoniae |
US6326136B1 (en) * | 1988-04-01 | 2001-12-04 | Digene Corporation | Macromolecular conjugate made using unsaturated aldehydes |
US20040037846A1 (en) * | 2000-10-02 | 2004-02-26 | Jackson W. James | Chlamydia pmp proteins, gene sequences and uses thereof |
US6699678B1 (en) | 1997-06-19 | 2004-03-02 | Savyon Diagnostics Ltd. | Chlamydia trachomatis specific peptides and their use in diagnostic assays |
US20050084862A1 (en) * | 2001-12-24 | 2005-04-21 | Helen Lee | Sample preparation for the detection of infectious agents |
US20050158793A1 (en) * | 2003-09-30 | 2005-07-21 | Shiroo Muraoka | Immunoassays |
US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
US20110014210A1 (en) * | 2006-01-16 | 2011-01-20 | Government of the US, as represented by the Secret ary, Department of Health and Human Services | Chlamydia vaccine |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI63778C (en) * | 1981-12-15 | 1983-08-10 | Labsystems Oy | FOERFARANDE FOER ISOLERING AV KLAMYDIA |
US4663291A (en) * | 1984-07-06 | 1987-05-05 | Becton, Dickinson And Company | Method for solubilizing microbial protein obtained from Chlamydia trachomatis |
GB8426468D0 (en) * | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
GB8427006D0 (en) * | 1984-10-25 | 1984-11-28 | Iq Bio Ltd | Determination of chlamydia trachomatis |
ATE143414T1 (en) * | 1985-01-14 | 1996-10-15 | Chiron Corp | MAIN PROTEIN OF THE OUTER MEMBRANE OF CHLAMYDIA |
US5006472A (en) * | 1988-06-03 | 1991-04-09 | Miles Inc. | Enzymatic purification process |
FI883067A (en) * | 1988-06-27 | 1989-12-28 | Labsystems Oy | FOERFARANDE FOER BEHANDLING AV KORONARKAERLSJUKDOM. |
US5116726A (en) * | 1988-07-25 | 1992-05-26 | Syntex (U.S.A.) Inc. | Methods for removal of detergents from analytes |
DK39592D0 (en) * | 1992-03-25 | 1992-03-25 | Safefood Micro Systsm As | METHOD OF DETECTING MICROORGANISMS |
US6464979B1 (en) * | 1996-09-12 | 2002-10-15 | Aventis Pasteur Limited | Chlamydial vaccines and methods of preparation thereof |
RU2485972C1 (en) * | 2011-11-15 | 2013-06-27 | Федеральное государственное бюджетное учреждение "Федеральный Центр токсикологической, радиационной и биологической безопасности" (ФГБУ "ФЦТРБ-ВНИВИ") | Method for producing antigen for retrospective diagnosis of animal chlamydial infection |
JP2016216413A (en) * | 2015-05-25 | 2016-12-22 | 国立大学法人山口大学 | Method for preparing antigen derived from bacterial cell belonging to bartonellaceae |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4118469A (en) | 1976-04-27 | 1978-10-03 | Research Corporation | Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU) |
-
1981
- 1981-03-03 US US06/240,223 patent/US4427782A/en not_active Expired - Lifetime
-
1982
- 1982-01-28 CA CA000395080A patent/CA1186223A/en not_active Expired
- 1982-02-04 AU AU80190/82A patent/AU549025B2/en not_active Expired - Fee Related
- 1982-02-26 EP EP82301003A patent/EP0059624B1/en not_active Expired
- 1982-02-26 DE DE8282301003T patent/DE3266888D1/en not_active Expired
- 1982-03-03 JP JP57032517A patent/JPS57158725A/en active Granted
-
1995
- 1995-04-11 JP JP7085455A patent/JP2773816B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4118469A (en) | 1976-04-27 | 1978-10-03 | Research Corporation | Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU) |
Non-Patent Citations (7)
Title |
---|
Banks et al., Infection and Immunity, vol. 20, 1978, pp. 864-866. |
Caldwell et al., Infection and Immunity, vol. 31, 1981, pp. 1161-1176. |
Caldwell et al., J. Immunol., vol. 115, 1975, pp. 969-975. |
Caldwell et al., J. Immunol., vol. 118, 1977, pp. 437-441. |
Caldwell et al., J. Immunol., vol. 118, 1977, pp. 442-445. |
Schuller et al., Lancet, 6 Jan. 1979, pp. 19-20. |
Taylor-Robinson et al., Lancet, 2 Jun. 1979, pp. 1162-1163. |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4497899A (en) * | 1982-04-12 | 1985-02-05 | Abbott Laboratories | Immunoassay for Chlamydia trachomatis antigens |
US4683196A (en) * | 1983-12-12 | 1987-07-28 | Meru, Inc. | Method and materials for the identification of lipopolysaccharide producing microorganisms |
US4766065A (en) * | 1984-08-23 | 1988-08-23 | Becton Dickinson And Company | Detection of cell membrane protein |
US6030799A (en) * | 1985-01-14 | 2000-02-29 | Washington Research Foundation | Immunoassays for detecting chlamydial antigens or antibodies thereto using recombinant or synthetic major outer membrane protein polypeptides as substitute antigens |
US4981685A (en) * | 1986-03-07 | 1991-01-01 | Utah State University Foundation | Bacterial extract vaccines for veterinary application |
WO1987007147A1 (en) * | 1986-05-28 | 1987-12-03 | Murex Corporation | Method for producing monoclonal antibodies to an immunogenic antibody-antigen conjunction |
US5300632A (en) * | 1986-11-18 | 1994-04-05 | Research Foundation Of State University Of New York | Method for purifying an outer membrane protein of Haemophilus influenzae |
US4959303A (en) * | 1987-12-21 | 1990-09-25 | Syntex (U.S.A.) Inc. | Assay for antigens by binding immune complexes to solid supports free of protein and non-ionic binders |
US4916057A (en) * | 1988-02-29 | 1990-04-10 | Kallestad Diagnostics, Inc. | Chlamydia assay employing base treatment |
US6326136B1 (en) * | 1988-04-01 | 2001-12-04 | Digene Corporation | Macromolecular conjugate made using unsaturated aldehydes |
US5075221A (en) * | 1988-10-07 | 1991-12-24 | Eastman Kodak Company | Stabilized extraction composition containing a sulfhydryl-containing reducing agent and its use in chlamydial and gonococcal determinations |
US5132205A (en) * | 1988-10-07 | 1992-07-21 | Eastman Kodak Company | High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen |
US5869608A (en) * | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
US6384206B1 (en) | 1989-03-17 | 2002-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
US5474900A (en) * | 1990-03-16 | 1995-12-12 | Sekisui Chemical Co., Ltd. | Process for preparing purified syphilis antigen from Treponema palljdum |
US5318892A (en) * | 1990-05-08 | 1994-06-07 | Hitachi Chemical Co., Ltd. | Method for assaying antibody against Chlamydia trachomatis and diagnostic preparation for chlamydia trachomatis infection |
US5725863A (en) * | 1991-09-06 | 1998-03-10 | The United States Of America As Represented By The Secretary Of Agriculture | Polypeptides useful in prevention of chlamydia infection |
US5212062A (en) * | 1991-09-06 | 1993-05-18 | Kansas State University | Method and composition to direct Chlamydia psittaci or Chlamydia trachomatis infection |
US5516638A (en) * | 1992-11-18 | 1996-05-14 | Calypte, Inc. | Immunoassays for the detection of antibodies to Chlamydia trachomatisi in the urine. |
US5484706A (en) * | 1993-05-19 | 1996-01-16 | Pasteur Sanofi Diagnostics | Immunoassay for analytes in samples using alkylating agents |
US5554471A (en) * | 1995-10-12 | 1996-09-10 | Xerox Corporation | Combination of toners |
US6281199B1 (en) | 1996-10-18 | 2001-08-28 | Pfizer Inc. | Method of treatment of heart disease caused by Chlamydia pneumoniae |
US6699678B1 (en) | 1997-06-19 | 2004-03-02 | Savyon Diagnostics Ltd. | Chlamydia trachomatis specific peptides and their use in diagnostic assays |
US6642023B1 (en) | 1997-10-02 | 2003-11-04 | Antex Biologics, Inc | Chlamydia protein, gene sequence and uses thereof |
US7459524B1 (en) * | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
CN1911960B (en) * | 1997-10-02 | 2012-11-07 | 新兴产品开发盖瑟斯堡公司 | Chlamydia protein, gene sequence and uses thereof |
WO1999017741A1 (en) * | 1997-10-02 | 1999-04-15 | Antex Biologics Inc. | Chlamydia protein, gene sequence and uses thereof |
US20040067524A1 (en) * | 1997-10-02 | 2004-04-08 | Antex Biologics Inc. | Chlamydia protein, gene sequence and uses thereof |
US20050048557A1 (en) * | 1997-10-02 | 2005-03-03 | Jackson W. James | Chlamydia protein, gene sequence and uses thereof |
US7655246B2 (en) | 1997-10-02 | 2010-02-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and uses thereof |
US6887843B1 (en) | 1997-10-02 | 2005-05-03 | Antex Biologics, Inc. | Chlamydia protein, gene sequence and uses thereof |
US7534445B2 (en) | 1997-10-02 | 2009-05-19 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
AU752426B2 (en) * | 1997-10-02 | 2002-09-19 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and uses thereof |
US7419807B2 (en) | 1997-10-02 | 2008-09-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and uses thereof |
EP1862472A3 (en) * | 1997-10-02 | 2008-03-19 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and uses thereof |
US7803388B2 (en) | 2000-10-02 | 2010-09-28 | Emergent Product Development Gaithersburg, Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
US20070292425A1 (en) * | 2000-10-02 | 2007-12-20 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP Proteins, Gene Sequences and Uses Thereof |
US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
US7731980B2 (en) | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
US20070292437A1 (en) * | 2000-10-02 | 2007-12-20 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP Proteins, Gene Sequences and Uses Thereof |
US7851609B2 (en) | 2000-10-02 | 2010-12-14 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
US20040037846A1 (en) * | 2000-10-02 | 2004-02-26 | Jackson W. James | Chlamydia pmp proteins, gene sequences and uses thereof |
US20050084862A1 (en) * | 2001-12-24 | 2005-04-21 | Helen Lee | Sample preparation for the detection of infectious agents |
US20050158793A1 (en) * | 2003-09-30 | 2005-07-21 | Shiroo Muraoka | Immunoassays |
US20110014210A1 (en) * | 2006-01-16 | 2011-01-20 | Government of the US, as represented by the Secret ary, Department of Health and Human Services | Chlamydia vaccine |
US9259463B2 (en) * | 2006-01-16 | 2016-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Chlamydia vaccine |
US20170021007A1 (en) * | 2006-01-16 | 2017-01-26 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Chlamydia vaccine |
US10420829B2 (en) * | 2006-01-16 | 2019-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Chlamydia vaccine |
Also Published As
Publication number | Publication date |
---|---|
EP0059624A2 (en) | 1982-09-08 |
CA1186223A (en) | 1985-04-30 |
EP0059624A3 (en) | 1983-03-23 |
JP2773816B2 (en) | 1998-07-09 |
JPS57158725A (en) | 1982-09-30 |
JPH0835967A (en) | 1996-02-06 |
JPH0449659B2 (en) | 1992-08-12 |
EP0059624B1 (en) | 1985-10-16 |
AU549025B2 (en) | 1986-01-09 |
DE3266888D1 (en) | 1985-11-21 |
AU8019082A (en) | 1982-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4427782A (en) | Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis | |
Cherry et al. | Detection of Legionnaires disease bacteria by direct immunofluorescent staining | |
Verwey | A type-specific antigenic protein derived from the Staphylococcus | |
Stoenner et al. | Antigenic variation of Borrelia hermsii. | |
Yuan et al. | Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars | |
Cocito et al. | Preparation and properties of antigen 60 from Mycobacterium bovis BCG. | |
Manning et al. | Analysis of cytoplasmic antigens of the yeast and mycelial phases of Candida albicans by two-dimensional electrophoresis | |
US4118469A (en) | Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU) | |
JP3018553B2 (en) | Chlamydia trachomatis antibody measurement method and preparation for diagnosing chlamydia trachomatis infection | |
Lambert Jr et al. | Identification of Actinomyces israelii and Actinomyces naeslundii by fluorescent-antibody and agar-gel diffusion techniques | |
Dazzo et al. | Antigenic differences between infective and noninfective strains of Rhizobium trifolii | |
Ullmann et al. | Immunochemistry of the cell walls of Listeria monocytogenes | |
US4722891A (en) | Methods and compositions for detection of Legionnaires' disease | |
EP0623215B1 (en) | Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis | |
WO1990003575A1 (en) | Process for producing campylobacter pylori-specific antigens | |
EP0363089B1 (en) | Use of a protease in the extraction of chlamydial, gonococcal and herpes antigens | |
HINDERSSON et al. | Immunochemical characterization and purification of Treponema pallidum antigen TpD expressed by Escherichia coli K12 | |
Daniel et al. | Demonstration of a shared epitope among mycobacterial antigens using a monoclonal antibody. | |
Thirkill et al. | Application of monoclonal antibodies to detect intraocular mycoplasma antigens in Mycoplasma arthritidis-infected Sprague-Dawley rats | |
EP0174805B1 (en) | Immunodiagnostic methods | |
Gerencser | Chapter VI The Application of Fluorescent Antibody Techniques to the Identification of Actinomyces and Arachnia | |
KR0130047B1 (en) | Diagnosis reagent for scrub typhus | |
JP3684668B2 (en) | Production method of Chlamydia pneumoniae antigen | |
Graham et al. | Serological reactions of the genus Peptostreptococcus | |
Jackson et al. | The application of high resolution two‐dimensional polyacrylamide gel electrophoresis to the identification and purification of a protein, NG 8.4, present in Neisseria gonorrhoeae and the subsequent development of a radioimmunoassay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, BERK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CALDWELL HARLAN D.;SCHACTER JULIUS;REEL/FRAME:003857/0525;SIGNING DATES FROM 19810330 TO 19810413 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M171); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS - NONPROFIT ORG. (ORIGINAL EVENT CODE: SM03); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M285); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |